The company, the former animal health arm of Pfizer, said in a statement that it had received a call from William A. Ackman about the investment by his activist hedge fund.
By Abba's Aces: Pfizer Inc (NYSE:PFE) is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare. Show More Summary
Pfizer spun out its animal health unit, Zoetis, in 2013. Should Merck do the same?
Pfizer just let its animal health business out on its own. Should you buy?
In an attempt to further simplify its business and unlock shareholder value, Pfizer Inc. (NYSE:PFE) has been busy divesting itself of non-core assets. Last year, that involved the sale of its infant nutrition business to Nestle. And earlier this year, that simplification process led to Pfizer spinning off its animal health care division into a separate […]
Cryoport has reached agreement with Zoetis, the former animal health business unit of Pfizer, to expand the scope of the cold chain logistics services Cryoport is providing.
Entries are invited for the Zoetis/BPC Poultry Trainee of the Year Award – sponsored by Zoetis, formerly the animal health business unit of Pfizer Inc., and the British Poultry Council is now fully involved for the first time.
Zoetis, the former animal health business of Pfizer has marked its separation from Pfizer and first day as a fully independent company.
Animal health products company Zoetis becomes a completely independent company after 60 years as a part of Pfizer.
When spun out in a February IPO it still held a sizable stake in the animal health business, but now after an oversubscribed exchange offer the drugmaker has completed its exit. The offer allowed shareholders to exchange some, all or none of their shares for at a conversion rate of 0.9898 shares of the latter [...]
Zoetis™ Declares Third-Quarter 2013 Dividend FLORHAM PARK, N.J.--(BUSINESS WIRE)-- The Board of Directors of Zoetis Inc. ( NYS: ZTS ), formerly the animal health business of Pfizer Inc., has declared a third-quarter dividend payable to holders of the company's common stock of $0.065 per share. Show More Summary
By Jim Osman: Surprising the market with the speed of separation of its animal health business, Zoetis (ZTS), Pfizer announced a tax-free split-off via exchange offer (~80.2% stake in ZTS) on May 22, 2013, which was before the 180-day lockup period since the IPO of ZTS. Show More Summary
Pfizer Inc. (NYSE:PFE) recently completed the spin-off of its animal health unit, Zoetis Inc (NYSE:ZTS). The company offered to acquire its stake in Zoetis for a 7% discount, in exchange of all or part of its shareholding. This is subject to an upper limit of 0.9898 shares of Zoetis common stock per share of Pfizer [...]
Pfizer Inc. (NYSE:PFE) recently announced plans to sell its remaining 80% stake in animal-health company Zoetis Inc (NYSE:ZTS) after about four months on the public market. Margins and profits aren’t as high in the animal health business, which has pushed the world’s largest pharmaceutical company to streamline its focus. It also highlights a delicate Catch-22 for [...]
Owners of Pfizer Inc. (NYSE:PFE) stock have an animal of a decision to make. The pharma giant is giving shareholders a chance to exchange Pfizer stock for shares in Zoetis Inc (NYSE:ZTS), its former animal health business that was spun out in February. Pfizer Inc. (NYSE:PFE) still owns 80% of Zoetis but is willing to give [...]
Owners of Pfizer stock have an animal of a decision to make. The pharma giant is giving shareholders a chance to exchange Pfizer stock for shares in Zoetis, its former animal health business that was spun out in February. Pfizer still...Show More Summary
Pfizer recently announced plans to sell its remaining 80% stake in animal-health company Zoetis after about four months on the public market. Margins and profits aren't as high in the animal health business, which has pushed the world's largest pharmaceutical company to streamline its focus. Show More Summary
By Chris Katje: At the beginning of 2013, I selected pharmaceutical giant Pfizer (PFE) as one of my top ten stock picks for the year. Of the three reasons I gave for investing in the drug company, the spin-off of animal health unit Zoetis (ZTS) was the biggest. Show More Summary
Pfizer is busy downsizing from health-care conglomerate to a focused pharmaceutical company. It sold off its nutrition business to Nestle for $12 billion and spun out 20% of its animal health division into a new company, Zoetis, forShow More Summary
If pharmaceutical companies can break up, why not biotech companies? Following in the footsteps of Abbott Laboratories (NYSE:ABT) spinning out its drug division into AbbVie Inc (NYSE:ABBV), and Pfizer spinning out its animal health division into animal health products into Zoetis, Theravance Inc (NASDAQ:THRX) is splitting up. Show More Summary